The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
Open accessAbstract
BACKGROUND Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine benchmarks of progression free survival (PFS) and overall survival (OS), we performed a meta-analysis using individual patient level trial data. METHODS Individual patient variables and survival outcomes were requested from 29 trials published from 2000-2016. Univariable and multivariable analysis were performed for prognostic factors. The variability between trial arms and between therapeutic agents on PFS and OS was investigated. RESULTS OS data were available for 912 patients. The median PFS was 3.3 months (95%CI 2.9 to 3.6) and 6-month PFS rate was 27% (95% CI 24 to 30). Univariable analysis showed male sex, elevated (i.e. > vs ≤ upper limit of normal (ULN)) lactate dehydrogenase (LDH), elevated alkaline phosphatase (ALP) and diameter of the largest liver metastasis (≥3cm vs < 3cm) to be significantly associated with shorter PFS. Multivariable analysis showed male sex, elevated LDH, and elevated ALP were significantly associated with shorter PFS. The most significant factors associated with 6-month PFS rate, on both univariable and multivariable analysis were elevated LDH and ALP. The median OS was 10.2 months (95% CI 9.5 to 11.0) and 1 year OS was 43% (95% CI 40 to 47). The most significant prognostic factors for shorter OS by univariable and multivariable analysis were elevated LDH and elevated ALP. Patients treated with liver directed treatments had statistically significant longer PFS and OS. CONCLUSION Benchmarks of 6-month PFS and 1-year OS rates were determined accounting for prognostic factors. These may be used to facilitate future trial design and stratification in mUM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Egner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 5,997
Dhamu Kp Ramamoorthy, K. (2016) · Cited by 2,962
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462
Sample Size Tables for Clinical Studies
Machin, D., Campbell, M. J., Tan, S. B., & Tan, S. H. (2008) · Wiley eBooks · doi:10.1002/9781444300710 · Cited by 1,336
Uveal Melanoma: Trends in Incidence, Treatment, and Survival
Singh, A. D., Turell, M. E., & Topham, A. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.040 · Cited by 1,267
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Ma¨kitie, T., & Kivela¨, T. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,045
Sample Size Calculations in Clinical Research
Chow, S.-C., Wang, H., & Shao, J. (2003) · CRC Press eBooks · doi:10.1201/9780203911341 · Cited by 807
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dummer, R., Hauschild, A., Guggenheim, M., Keilholz, U., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds229 · Cited by 714
Self-citationKorn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.12.1639 · Cited by 621
Sample Size Calculations in Clinical Research
Chow, S.-C., Wang, H., & Shao, J. (2007) · doi:10.1201/9781584889830 · Cited by 562
Martin, M., Maßhöfer, L., Temming, P., Rahmann, S., Metz, C., Bornfeld, N., van de Nes, J., Klein-Hitpass, L., Hinnebusch, A. G., Horsthemke, B., et al. (2013) · Nature Genetics · doi:10.1038/ng.2674 · Cited by 542
Onken, M. D., Worley, L. A., Char, D. H., Augsburger, J. J., Correa, Z. M., Nudleman, E., Aaberg, T. M., Altaweel, M. M., Bardenstein, D. S., Finger, P. T., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.017 · Cited by 506
Sample Size Determination and Power
Ryan, T. P. (2013) · Wiley Series in Probability and Statistics · doi:10.1002/9781118439241 · Cited by 465
Carvajal, R. D., Sosman, J. A., Quevedo, J. F., Milhem, M. M., Joshua, A. M., Kudchadkar, R. R., Linette, G. P., Gajewski, T. F., Lutzky, J., Lawson, D. H., et al. (2014) · JAMA · doi:10.1001/jama.2014.6096 · Cited by 433
Self-citationSample size tables for exact single‐stage phase II designs
A'Hern, R. P. (2001) · Statistics in Medicine · doi:10.1002/sim.721 · Cited by 399
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dummer, R., Hauschild, A., Lindenblatt, N., Pentheroudakis, G., & Keilholz, U. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv297 · Cited by 396
Self-citationVariates of Survival in Metastatic Uveal Melanoma
Rietschel, P., Panageas, K. S., Hanlon, C., Patel, A., Abramson, D. H., & Chapman, P. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6534 · Cited by 316
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
Moore, A. R., Ceraudo, E., Sher, J. J., Guan, Y., Shoushtari, A. N., Chang, M. T., Zhang, J. Q., Walczak, E. G., Kazmi, M. A., Taylor, B. S., et al. (2016) · Nature Genetics · doi:10.1038/ng.3549 · Cited by 314
PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Field, M. G., Decatur, C. L., Kurtenbach, S., Gezgin, G., van der Velden, P. A., Jager, M. J., Kozak, K. N., & Harbour, J. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2071 · Cited by 293
Effectiveness of Treatments for Metastatic Uveal Melanoma
Augsburger, J. J., Corrêa, Z. M., & Shaikh, A. H. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.01.023 · Cited by 288
Carvajal, R. D., Piperno-Neumann, S., Kapiteijn, E., Chapman, P. B., Frank, S., Joshua, A. M., Piulats, J. M., Wolter, P., Cocquyt, V., Chmielowski, B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.1090 · Cited by 271
Self-citationZimmer, L., Vaubel, J., Mohr, P., Hauschild, A., Utikal, J., Simon, J., Garbe, C., Herbst, R., Enk, A., Kämpgen, E., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118564 · Cited by 269
Self-citationBiostatistical Methods: The Assessment of Relative Risks
Lachin, J. M. (2000) · Wiley Series in Probability and Statistics · doi:10.1002/9780470317051 · Cited by 200
Molecular pathology of uveal melanoma
Coupland, S. E., Lake, S. L., Zeschnigk, M., & Damato, B. E. (2013) · Eye · doi:10.1038/eye.2012.255 · Cited by 181
A prognostic model and staging for metastatic uveal melanoma
Eskelin, S., Pyrhönen, S. O., Hahka‐Kemppinen, M., Tuomaala, S., & Kivelä, T. (2003) · Cancer · doi:10.1002/cncr.11113 · Cited by 166
Self-citationSystemic treatment of metastatic uveal melanoma: review of literature and future perspectives
Buder, K., Gesierich, A., Gelbrich, G., & Goebeler, M. (2013) · Cancer Medicine · doi:10.1002/cam4.133 · Cited by 132
Patel, K., Sullivan, K. L., Berd, D., Mastrangelo, M. J., Shields, C. L., Shields, J. A., & Sato, T. (2005) · Melanoma Research · doi:10.1097/00008390-200508000-00011 · Cited by 120
Self-citationA phase 2 study of tremelimumab in patients with advanced uveal melanoma
Joshua, A. M., Monzon, J. G., Mihalcioiu, C. L. D., Hogg, D., Smylie, M., & Cheng, T. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000175 · Cited by 105
Self-citationValsecchi, M. E., Terai, M., Eschelman, D. J., Gonsalves, C. F., Chervoneva, I., Shields, J. A., Shields, C. L., Yamamoto, A., Sullivan, K. L., Laudadio, M., et al. (2015) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2014.11.037 · Cited by 98
Self-citationSchmittel, A. H., Schmidt‐Hieber, M., Martus, P., Bechrakis, N., Schuster, R., Siehl, J., Foerster, M. H., Thiel, E., & Keilholz, U. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl309 · Cited by 93
Self-citationBhatia, S., Moon, J., Margolin, K. A., Weber, J. S., Lao, C. D., Othus, M. K. D., Aparicio, A. M., Ribas, A., & Sondak, V. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048787 · Cited by 89
Self-citationAflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
Tarhini, A. A., Frankel, P. H., Margolin, K. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1463 · Cited by 87
Self-citationA pilot study of sunitinib malate in patients with metastatic uveal melanoma
Mahipal, A., Tijani, L., Chan, K. R., Laudadio, M., Mastrangelo, M. J., & Sato, T. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328358b373 · Cited by 85
Self-citationLong Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients
Bol, K. F., Mensink, H. W., Aarntzen, E. H. J. G., Schreibelt, G., KEUNEN, J. E. E., Coulie, P. G., de Klein, A., Punt, C. J. A., Paridaens, D. A., Figdor, C. G., et al. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.07.014 · Cited by 80
Phase II evaluation of temozolomide in metastatic choroidal melanoma
Bedikian, A. Y., Papadopoulos, N., Plager, C., Eton, O. E., & Ring, S. E. (2003) · Melanoma Research · doi:10.1097/00008390-200306000-00013 · Cited by 77
Penel, N., Delcambre, C., Durando, X., Clisant, S., Hebbar, M., Négrier, S., Fournier, C., Isambert, N., Mascarelli, F., & Mouriaux, F. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9143-2 · Cited by 56
Self-citationDevelopment and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma
Valpione, S., Moser, J. C., Parrozzani, R., Bazzi, M., Mansfield, A. S., D, S. M. M., Pigozzo, J., Midena, E., Markovic, S. N., Aliberti, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120181 · Cited by 49
Cited by
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103485 · Cited by 924
Self-citationNivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study
Pelster, M. S., Gruschkus, S. K., Bassett, R., Gombos, D. S., Shephard, M., Posada, L., Glover, M. S., Simien, R., Diab, A., Hwu, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.00605 · Cited by 301
Self-citationThree-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Hassel, J. C., Piperno-Neumann, S., Rutkowski, P., Baurain, J.-F., Schlaak, M., Butler, M. O., Sullivan, R. J., Dummer, R., Kirkwood, J. M., Orloff, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304753 · Cited by 284
Self-citationAdvances in the clinical management of uveal melanoma
Carvajal, R. D., Sacco, J. J., Jager, M. J., Eschelman, D. J., Olofsson Bagge, R., Harbour, J. W., Chieng, N. D., Patel, S. P., Joshua, A. M., & Piperno-Neumann, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00714-1 · Cited by 278
Self-citationMiddleton, M. R., McAlpine, C., Woodcock, V. K., Corrie, P., Infante, J. R., Steven, N. M., Evans, T. R. J., Anthoney, A., Shoushtari, A. N., Hamid, O., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1247 · Cited by 275
Metadata
- Authors
- Khoja, L., Atenafu, E. G., Suciu, S., Leyvraz, S., Sato, T., Marshall, E., Keilholz, U., Zimmer, L., Patel, S. P., Piperno-Neumann, S., Piulats, J., Kivelä, T. T., Pfoehler, C., Bhatia, S., Huppert, P., Van Iersel, L. B. J., De Vries, I. J. M., Penel, N., Vogl, T., Cheng, T., Fiorentini, G., Mouriaux, F., Tarhini, A., Patel, P. M., Carvajal, R., & Joshua, A. M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 30
- Issue
- 8
- Pages
- 1370-1380
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2947820344
- Cited by
- 286
- References
- 42
- FWCI
- 24.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.